The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Open accessAbstract
Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigated using both in vitro studies employing recombinant apoE and in vivo studies in wild-type and apoE(-/-) mice. Receptor dependence was explored in vitro and in vivo using low-density lipoprotein receptor (LDLR(-/-))-deficient mice. As an alternative to endogenous apoE-based targeting, we developed a targeting approach using an exogenous ligand containing a multivalent N-acetylgalactosamine (GalNAc)-cluster, which binds with high affinity to the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. Both apoE-based endogenous and GalNAc-based exogenous targeting appear to be highly effective strategies for the delivery of iLNPs to liver.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At blood pH, LNPs exhibit a net neutral surface charge but become positively charged in acidified endosomes following ApoE-mediated endocytosis by hepatocytes in vivo, resulting in endosome disruption and release of mRNA into the cytoplasm.28,41,45”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [45]
In the citing paper
“Previous work has shown that LNP systems with this lipid composition can silence target genes in hepatocytes following IV injection at dose levels as low as 0.01 mg siRNA/kg body weight8,9 in an apolipoprotein E (ApoE)–dependent fashion.10”
From Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain (2013) · cites this paper as [10]
In the citing paper
“Detailed studies have shown that the ability of LNP-siRNA systems containing related ionizable cationic lipids to induce hepatocyte gene knockdown in vivo is ApoE dependent.10”
From Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain (2013) · cites this paper as [10]
In the citing paper
“In ApoE knockout mice, LNP-siRNA gene silencing activity is inhibited in hepatocytes and can be reestablished by incubating the LNPs with ApoE before IV administration.”
From Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain (2013) · cites this paper as [10]
In the citing paper
“Upon intravenous administration, Akinc et al. found that the surface of neutrally-charged LNPs is strongly enriched with apolipoprotein E (ApoE), which leads to enhanced uptake by hepatocytes through low density lipoprotein (LDL) receptor-mediated endocytosis [40]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [40]
In the citing paper
“As example, Akinc et al. found that the selective adsorption of apolipoprotein E onto an ionizable (neutral) LNP was responsible for the specific and potent delivery of (si)RNA to hepatocytes through receptor mediated endocytosis [156].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [156]
In the citing paper
“one potential mechanism of hepatocyte targeting effect by LNPs involves the interaction of ionizable LNPs with apolipoprotein E (apoE), a protein that facilitates the transport of molecules such as lipids and cholesterol.[59, 60] Binding on the surface of LNPs, apoE mediated the hepatocellular uptake of LNPs through multiple receptors, such as the low-density lipoprotein receptor (LDLR).[59, 60]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [60]
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Allen, T. M., Hansen, C., Martin, F., Redemann, C. T., & Yau‐Young, A. O. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90246-5 · Cited by 1,392
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein
Beisiegel†, U., Weber, W. T., Ihrke, G., Herz, J., & Stanley, K. K. (1989) · Nature · doi:10.1038/341162a0 · Cited by 680
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 645
Research works printed but not linked: 1
- Immordino, 2006, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int J Nanomedicine, 1, 297
Cited by
Sorted by citations
Items 601–700 of 1,002
Akita, H., Nakatani, T., Kuroki, K., Maenaka, K., Tange, K., Nakai, Y., & Harashima, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.043 · Cited by 30
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Suzuki, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02566 · Cited by 29
Identification of Cell Receptors Responsible for Recognition and Binding of Lipid Nanoparticles
Baimanov, D., Wang, J., Liu, Y., Zheng, P., Yu, S., Liu, F., Wang, J., Boraschi, D., Zhao, Y., Chen, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16987 · Cited by 31
Immune responses of therapeutic lipid nanoparticles
Chen, W. C., May, J. P., & Li, S. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2012-0040 · Cited by 29
Use, exposure and omics characterisation of potential hazard in nanomaterials
Ling, N., Zhang, N., Yong, W. T. L., Misbah, S., Hashim, F., Soon, C. F., Lim, G. P., Peng, W., & Sonne, C. (2023) · Materials Today Advances · doi:10.1016/j.mtadv.2023.100341 · Cited by 31
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?
Philippen, L. E., Dirkx, E., Wit, J. B. M., Burggraaf, K., Windt, L. J. D., & Martins, P. A. D. C. (2015) · Molecular Therapy · doi:10.1038/mt.2015.133 · Cited by 29
Schmidt, P. J., Liu, K., Visner, G. A., Fitzgerald, K. J., Fishman, S., Racie, T., Hettinger, J. L., Butler, J. S., & Fleming, M. D. (2018) · American Journal of Hematology · doi:10.1002/ajh.25079 · Cited by 31
Kim, J., Mukherjee, A., Nelson, D., Jozic, A., & Sahay, G. (2020) · doi:10.1101/2020.07.24.205583 · Cited by 28
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 31
Immunomodulatory Therapy for Ischemic Heart Disease
Zhao, X., Williamson, T., Gong, Y., Epstein, J. A., & Fan, Y. (2024) · Circulation · doi:10.1161/circulationaha.124.070368 · Cited by 28
The Interplay of Endosomal Escape and RNA Release from Polymeric Nanoparticles
Cheung, T. H., & Shoichet, M. S. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c05176 · Cited by 33
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Wan, P., Tang, S., Yang, T., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., et al. (2025) · Nature Medicine · doi:10.1016/j.atherosclerosis.2025.119507 · Cited by 41
Conjugates of small targeting molecules to non-viral vectors for the mediation of siRNA
Zhi, D., Zhao, Y., Cui, S., Chen, H., & Zhang, S. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.03.048 · Cited by 28
Efficient Shielding of Polyplexes Using Heterotelechelic Polysarcosines
Klein, P. M., Klinker, K., Zhang, W., Kern, S., Kessel, E., Wagner, E., & Barz, M. (2018) · Polymers · doi:10.3390/polym10060689 · Cited by 29
Aliyandi, A., Zuhorn, I. S., & Salvati, A. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.599454 · Cited by 30
“Another study also showed that ionizable lipid nanoparticles could naturally adsorb apolipoprotein-E (ApoE), leading to enhanced uptake into hepatocyte via several receptors that contain ApoE binding ligands (Akinc et al., 2010; Williams and Chen, 2010).”
BackgroundAnisotropic expansion of hepatocyte lumina enforced by apical bulkheads
Belicová, L., Repnik, U., Delpierre, J., Gralinska, E., Seifert, S., Valenzuela, J. I., Morales-Navarrete, H. A., Franke, C., Räägel, H., Shcherbinina, E. Y., et al. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103003 · Cited by 27
Vaillant, A. (2022) · Viruses · doi:10.3390/v14092052 · Cited by 30
Elwakil, M. M. A., Suzuki, R., Khalifa, A. M., Elshami, R. M., Isono, T., Elewa, Y. H. A., Sato, Y., Nakamura, T., Satoh, T., & Harashima, H. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303795 · Cited by 30
Therapeutic Oligonucleotides with Polyethylene Glycol Modifications
Winkler, J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.94 · Cited by 27
Nano-carriers for drug routeing – towards a new era
Reddy, L. H., & Bazile, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1561891 · Cited by 28
Oligonucleotide therapeutics and their chemical modification strategies for clinical applications
Kim, H., Kim, S., Lee, D., Lee, D., Yoon, J., & Lee, H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00669-8 · Cited by 30
He, X., Wang, R., Cao, Y., Ding, Y., Chang, Y., Dong, H., Xie, R., Zhong, G., Yang, H., & Li, J. (2025) · Advanced Science · doi:10.1002/advs.202416525 · Cited by 29
Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology
Gomes-da-Silva, L. C., Simões, S., & Moreira, J. N. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1502-2 · Cited by 27
Increased PIP3 activity blocks nanoparticle mRNA delivery
Paunovska, K., Sanchez, A. D. S., Foster, M. T., Loughrey, D., Blanchard, E. L., Islam, F. Z., Gan, Z., Mantalaris, A., Santangelo, P. J., & Dahlman, J. E. (2020) · Science Advances · doi:10.1126/sciadv.aba5672 · Cited by 26
Sato, Y. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00705 · Cited by 29
Recent Advances in RNA Therapy and Its Carriers to Treat the Single-Gene Neurological Disorders
Lee, M., Lee, I., & Wang, K. (2022) · Biomedicines · doi:10.3390/biomedicines10010158 · Cited by 27
“By interacting with the low-density lipoprotein (LDL) receptor, apolipoprotein E, and other opsonins, the nanoparticles are internalized into the hepatocytes [66].”
BackgroundKhoja, S., Liu, X.-B., Truong, B., Nitzahn, M., Lambert, J., Eliav, A., Nasser, E., Randolph, E., Burke, K. E., White, R. A., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.012 · Cited by 26
Sekar, R., Motzler, K., Kwon, Y., Novikoff, A., Jülg, J., Najafi, B., Wang, S., Warnke, A.-L., Seitz, S., Hass, D., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.022 · Cited by 30
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 27
Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines
Hazan‐Halevy, I., Landesman‐Milo, D., Rosenblum, D., Mizrahy, S., Ng, B. D., & Peer, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.052 · Cited by 27
Trends in the Binding of Cell Penetrating Peptides to siRNA: A Molecular Docking Study
Rathnayake, P. V. G. M., Gunathunge, B. C. M., Wimalasiri, P. N., Karunaratne, D. N., & Ranatunga, R. J. K. U. (2017) · Journal of Biophysics · doi:10.1155/2017/1059216 · Cited by 27
Mechanisms and Delivery of tRNA Therapeutics
Ward, C., Beharry, A., Tennakoon, R., Rozik, P., Wilhelm, S. D. P., Heinemann, I. U., & O’Donoghue, P. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00142 · Cited by 25
Physiology, pathology and the biomolecular corona: the confounding factors in nanomedicine design
Liu, K., Salvati, A. L., & Sabirsh, A. (2022) · Nanoscale · doi:10.1039/d1nr08101b · Cited by 26
Chen, W., Chen, Y., Ren, Y., Gao, C., Ning, C., Deng, H., Li, P., Ma, Y., Li, H., Fu, L., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121888 · Cited by 27
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
Liu, W., Alameh, M., Yang, J. F., Xu, J. R., Lin, P. J. C., Tam, Y. K., Weissman, D., & You, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314504 · Cited by 33
Poly(aspartic acid)-Based Polymeric Nanoparticle for Local and Systemic mRNA Delivery
Park, Y., Moses, A. S., Demessie, A. A., Singh, P., Lee, H., Korzun, T., Taratula, O. R., Alani, A. W. G., & Taratula, O. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00738 · Cited by 26
Xue, H. Y., & Wong, H. L. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.02.005 · Cited by 26
Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA
Wilner, S. E., & Levy, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3197-2_18 · Cited by 28
Lipidoid Tail Structure Strongly Influences siRNA Delivery Activity
Knapp, C. M., Guo, P., & Whitehead, K. A. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0436-9 · Cited by 26
Toriyabe, N., Sakurai, Y., Kato, A., Yamamoto, S., Tange, K., Nakai, Y., Akita, H., & Harahsima, H. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.042 · Cited by 27
Phospholipid‐Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver
Zhang, W., Böttger, R., Qin, Z., Kulkarni, J. A., Vogler, J., Cullis, P. R., & Li, S. (2019) · Small · doi:10.1002/smll.201901782 · Cited by 27
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
“These are widely used to deliver RNA therapeutics to liver cells as they have a natural tropism mediated by surface adsorption of serum ApoE which facilitates low density lipoprotein receptor (LDLR) binding and subsequent transfection (75).”
BackgroundMethodSato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.006 · Cited by 25
Intelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 28
From in vitro to in vivo: The Dominant role of PEG-Lipids in LNP performance
Borah, A., Giacobbo, V., Binici, B., Baillie, R., & Perrie, Y. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114726 · Cited by 28
Long non-coding RNAs in immune regulation and their potential as therapeutic targets
Kumar, D. B. U., & Williams, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106279 · Cited by 25
Pei, Y., Bao, Y., Sacchetti, C., Brady, J., Gillard, K., Yu, H., Roberts, S., Rajappan, K., Tanis, S. P., Pérez‐García, C. G., et al. (2022) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2022.105178 · Cited by 26
Lin, C., Jans, A., Wolters, J. C., Mohamed, M. R., van der Vorst, E. P. C., Trautwein, C., & Bartneck, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202670 · Cited by 25
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
Rodrigueza, W. V., Woolliscroft, M. J., Ebrahim, A.-S., Forgey, R. W., McGovren, P. J., Endert, G., Wagner, A., Holewa, D. D., Aboukameel, A., Gill, R. D., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2476-y · Cited by 27
Togashi, R., Tanaka, H., Nakamura, S., Yokota, H., Tange, K., Nakai, Y., Yoshioka, H., Harashima, H., & Akita, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.022 · Cited by 25
Current Status of Messenger RNA Delivery Systems
Stanton, M. G. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0726 · Cited by 26
Surface modification of lipid nanoparticles for gene therapy
Tafech, B., Mohabatpour, F., & Hedtrich, S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3642 · Cited by 25
Zhang, Q., Wu, S., Chen, Q., Zhang, Y., Zhang, C., Yin, R., Ouyang, Z., & Wei, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12071505 · Cited by 25
Senapedis, W. T., Gallagher, K. M., Figueroa, E., Farelli, J. D., Lyng, R., Hodgson, J., O’Donnell, C. W., Newman, J. V., Pacaro, M., Siecinski, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52202-y · Cited by 24
Targeted Delivery of RNAi Therapeutics for Cancer Therapy
Li, J., & Huang, L. (2010) · Nanomedicine · doi:10.2217/nnm.10.124 · Cited by 24
Nakagawa, O., Ming, X., Carver, K. A., & Juliano, R. L. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400500h · Cited by 24
Elwakil, M. M. A., Gao, T., Isono, T., Sato, Y., Elewa, Y. H. A., Satoh, T., & Harashima, H. (2021) · Materials Horizons · doi:10.1039/d1mh00185j · Cited by 24
Golba, B., Soete, M., Zhong, Z., Sanders, N. N., Prez, F. D., Houck, H. A., & Geest, B. G. D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301102 · Cited by 25
Spherical nucleic acids-based nanoplatforms for tumor precision medicine and immunotherapy
Liu, S., Yu, C., & Wei, H. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100750 · Cited by 25
Sun, H., Zhang, Y., Wang, J., Su, J., Zhou, D., Yu, X., Xu, Y., & Yang, W. (2023) · Theranostics · doi:10.7150/thno.86466 · Cited by 27
Unveiling the challenges of engineered protein corona from the proteins’ perspective
Marques, C., Borchard, G., & Jordan, O. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123987 · Cited by 25
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 27
Kenny, G., Villegas-Llerena, C., Tagalakis, A., Campbell, F., Welser, K., Botta, M., Tabor, A., Hailes, H., Lythgoe, M., & Hart, S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.042 · Cited by 24
Zhou, C., Zhang, Y., Yu, B., Phelps, M. A., Lee, L. J., & Lee, R. J. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.10.002 · Cited by 24
Emerging Progress of RNA-Based Antitumor Therapeutics
Fu, J., Dong, H., Wu, J., & Jin, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83732 · Cited by 23
RNA-based therapies in liver metabolic diseases
Fontanellas, A., Berraondo, P., Urigo, F., Jericó, D., Martini, P. G. V., Pastor, F., & Avila, M. A. (2025) · Gut · doi:10.1136/gutjnl-2023-331742 · Cited by 31
Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 28
Niederkofler, S., Parkkila, P., Aliakbarinodehi, N., Sasanian, N., Emilsson, G., Ulkoski, D., Ferreira, C. J. O., Galenkamp, N. S., Silva, B. F. B., Lundberg, D., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c17052 · Cited by 23
Pancreatic-targeted lipid nanoparticles based on organ capsule filtration
Lei, J., Yang, K., Cao, W., Qi, S., Du, X., Li, H., Wang, Y., Gan, J., Feng, Y., Li, Y., et al. (2026) · Nature · doi:10.1038/s41586-026-10158-7 · Cited by 28
Oliveira, C. L., Silveira, I., Veiga, F., & Ribeiro, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.945421 · Cited by 23
CRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 25
Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides
Zeng, Y., Shen, M., Pattipeiluhu, R., Zhou, X., Zhang, Y., Bakkum, T., Sharp, T. H., Boyle, A. L., & Kros, A. (2023) · Nanoscale · doi:10.1039/d3nr02175k · Cited by 24
Fritz, T., Voigt, M., Worm, M., Negwer, I., Müller, S. S., Kettenbach, K., Roß, T. L., Roesch, F., Koynov, K., Frey, H., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201602758 · Cited by 23
Zhou, K., Johnson, L. T., Xiong, H., Barrios, S., Minnig, J. T., Yan, Y., Abram, B., Yu, X., & Siegwart, D. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01288 · Cited by 23
Understanding In Vivo Fate of Nucleic Acid and Gene Medicines for the Rational Design of Drugs
Fumoto, S., Yamamoto, T., Okami, K., Maemura, Y., Terada, C., Yamayoshi, A., & Nishida, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020159 · Cited by 23
Enhancing siRNA delivery by employing lipid nanoparticles
Hope, M. J. (2014) · Therapeutic Delivery · doi:10.4155/tde.14.37 · Cited by 22
Self-citationWNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials
Lehrich, B. M., & Monga, S. P. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01127-y · Cited by 27
“Programmed packaging” for gene delivery
Hyodo, M., Sakurai, Y., Akita, H., & Harashima, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.023 · Cited by 23
Tuettenberg, A., Steinbrink, K., & Schuppan, D. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0208 · Cited by 22
Lectin recognition and hepatocyte endocytosis of GalNAc-decorated nanostructured lipid carriers
Gauthier, L., Chevallet, M., Bulteau, F., Thépaut, M., Delangle, P., Fieschi, F., Vivès, C., Texier, I., Deniaud, A., & Gateau, C. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1806286 · Cited by 22
A proposed mathematical description of in vivo nanoparticle delivery
Wu, J. L. Y., Stordy, B. P., Nguyen, L. N. M., Deutschman, C. P., & Chan, W. C. W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114520 · Cited by 24
Talaat, S. M., Elnaggar, Y. S. R., El-Ganainy, S. O., Gowayed, M. A., Abdel-Bary, A., & Abdallah, O. Y. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122184 · Cited by 22
mRNA-Based Approaches to Treating Liver Diseases
Cacicedo, M. L., Limeres, M. J., & Gehring, S. (2022) · Cells · doi:10.3390/cells11203328 · Cited by 23
Small RNAs: An expanding world with therapeutic promises
Gou, L., Zhu, Q., & Liu, M. (2023) · Fundamental Research · doi:10.1016/j.fmre.2023.03.003 · Cited by 22
Lehrich, B. M., & Delgado, E. R. (2024) · Organogenesis · doi:10.1080/15476278.2024.2313696 · Cited by 24
siRNA Delivery for the treatment of ovarian cancer
Goldberg, M. S. (2013) · Methods · doi:10.1016/j.ymeth.2013.01.007 · Cited by 22
Recent advances in the targeting of systemically administered non-viral gene delivery systems
Khalil, I. A., Sato, Y., & Harashima, H. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1656196 · Cited by 22
Recent Developments in Delivery of MicroRNAs Utilizing Nanosystems for Metabolic Syndrome Therapy
Li, T., Zhu, L., Zhu, L., Wang, P., Xu, W., & Huang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157855 · Cited by 23
Irf5 siRNA-loaded biodegradable lipid nanoparticles ameliorate concanavalin A-induced liver injury
Kawase, W., Kurotaki, D., Suzuki, Y., Ishihara, H., Ban, T., Sato, G. R., Ichikawa, J., Yanai, H., Taniguchi, T., Tsukahara, K., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.023 · Cited by 22
“independent mechanism Previous reports have suggested that biodegradable LNPs are incorporated into hepatocytes via the ApoE-LDLR pathway.(16,36) To investigate whether the ApoE-LDLR pathway is involved in incorporating biodegradable LNPs used in this study into macrophages, we injected them into ApoE-deficient mice.”
BackgroundAdvances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Rademacker, S., Carneiro, S. P., Molbay, M., Catapano, F., Forné, I., Imhof, A., Wibel, R., Heidecke, C., Hölig, P., & Merkel, O. M. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107182 · Cited by 21
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery
Jozić, A., Roux, C. L., Kim, J., Berchel, M., Sahel, D. K., Bodi, E., Palumbo, M., Vasudevan, A., Murthy, N. T. V., Eygeris, Y., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03022-6 · Cited by 27
Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy
Marschall, A. L. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00500-y · Cited by 22
Bogaert, B., Debisschop, A., Ehouarne, T., Eeckhoutte, H. P. V., Volder, J. D., Jacobs, A., Pottie, E., Rycke, R. M. D., Crabbé, A., Mestdagh, P., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03345 · Cited by 22
Gupta, K., Mattingly, S. J., Knipp, R. J., Afonin, K. A., Viard, M., Bergman, J. T., Stepler, M., Nantz, M. H., Puri, A., & Shapiro, B. A. (2015) · Nanomedicine · doi:10.2217/nnm.15.105 · Cited by 21
Saneyoshi, H., Iketani, K., Kondo, K., Saneyoshi, T., Okamoto, I., & Ono, A. M. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00368 · Cited by 21
Drug Delivery Strategies for Antivirals against Hepatitis B Virus
Singh, L., Indermun, S., Govender, M., Kumar, P., du Toit, L. C., Choonara, Y. E., & Pillay, V. (2018) · Viruses · doi:10.3390/v10050267 · Cited by 21
Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection
Kon, E., Hazan‐Halevy, I., Rosenblum, D., Cohen, N., Chatterjee, S., Veiga, N., Raanani, P., Bairey, O., Benjamini, O., Nagler, A., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060520 · Cited by 21
The Roles of Individual Mammalian Argonautes in RNA Interference In Vivo
Ruda, V. M., Chandwani, R., Sehgal, A., Bogorad, R. L., Akinc, A., Charissé, K., Tarakhovsky, A., Novobrantseva, T. I., & Koteliansky, V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101749 · Cited by 21
Metadata
- Authors
- Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., Butler, J. S., Qin, L., Racie, T., Sprague, A., Fava, E., Zeigerer, A., Hope, M. J., Zerial, M., Sah, D. W., Fitzgerald, K., Tracy, M. A., Manoharan, M., Koteliansky, V., Fougerolles, A. D., & Maier, M. A.
- Affiliations
- Alnylam Pharmaceuticals (United States) (US)
- Max Planck Institute of Molecular Cell Biology and Genetics (DE)
- Corresponding author
- Akinc, Akin
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 18
- Issue
- 7
- Pages
- 1357-1364
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC2911264
- OpenAlex
- W2143743183
- Cited by
- 1,261
- References
- 32
- Citations by year
- 2026: 147 · 2025: 141 · 2024: 164 · 2023: 129 · 2022: 120 · 2021: 83 · 2020: 72 · 2019: 63 · 2018: 39 · 2017: 41 · 2016: 47 · 2015: 46 · 2014: 51 · 2013: 46 · 2012: 44
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Alnylam Pharmaceuticals
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- RNAi therapeutics, lipid nanoparticles, apolipoprotein E, N-acetylgalactosamine, asialoglycoprotein receptor, hepatocyte targeting, LDL receptor, nanoparticle clearance
- MeSH terms
- Animals, Apolipoproteins E, Female, HeLa Cells, Humans, Ligands, Mice, Inbred C57BL, Receptors, LDL, Hepatocytes, RNA Interference, Asialoglycoprotein Receptor, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
